Natera (NASDAQ:NTRA) has been analyzed by 10 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 6 | 4 | 0 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 3 | 2 | 0 | 0 | 0 |
| 2M Ago | 2 | 1 | 0 | 0 | 0 |
| 3M Ago | 0 | 1 | 0 | 0 | 0 |
Analysts have set 12-month price targets for Natera, revealing an average target of $121.8, a high estimate of $142.00, and a low estimate of $100.00. Witnessing a positive shift, the current average has risen by 23.2% from the previous average price target of $98.86.
Decoding Analyst Ratings: A Detailed Look
The perception of Natera by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Tycho Peterson | Jefferies | Announces | Buy | $142.00 | - |
| David Westenberg | Piper Sandler | Raises | Overweight | $120.00 | $110.00 |
| Mark Massaro | BTIG | Raises | Buy | $125.00 | $100.00 |
| Kyle Mikson | Canaccord Genuity | Raises | Buy | $130.00 | $100.00 |
| Dan Brennan | TD Cowen | Raises | Buy | $137.00 | $123.00 |
| Catherine Ramsey | Baird | Raises | Outperform | $117.00 | $99.00 |
| Matthew Sykes | Goldman Sachs | Raises | Buy | $100.00 | $90.00 |
| Alexander Nowak | Craig-Hallum | Announces | Buy | $117.00 | - |
| Eve Burstein | Bernstein | Announces | Outperform | $120.00 | - |
| David Westenberg | Piper Sandler | Raises | Overweight | $110.00 | $70.00 |
Key Insights:
- Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Natera. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Natera compared to the broader market.
- Price Targets: Delving into movements, analysts provide estimates for the future value of Natera's stock. This analysis reveals shifts in analysts' expectations over time.
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Natera's market standing. Stay informed and make data-driven decisions with our Ratings Table.
Stay up to date on Natera analyst ratings.
Delving into Natera's Background
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
Financial Milestones: Natera's Journey
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Natera's remarkable performance in 3 months is evident. As of 31 March, 2024, the company achieved an impressive revenue growth rate of 52.11%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Natera's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -18.38%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -8.67%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Natera's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -4.65%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Natera's debt-to-equity ratio is below the industry average at 0.55, reflecting a lower dependency on debt financing and a more conservative financial approach.
The Significance of Analyst Ratings Explained
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
This article was generated by Benzinga's automated content engine and reviewed by an editor.